ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,459.10
1.11%
US Tech 100
18,522.40
1.05%
Dow Jones
40,589.34
1.64%
Brent Oil
79.745
0.00%
Bitcoin
67,745.90
-0.25%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Passage Bio Inc (PASG) Quote

Passage Bio Inc

Passage Bio Inc (PASG)

NASDAQ
0.917
0.037
(4.20%)
Closed July 26 4:00PM
Delayed by 15 minutes
0.917
0.00
(0.00%)
After Hours: 6:40PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
0.917
Bid
0.8803
Ask
0.918
Volume
80,364
0.853301 Day's Range 0.918
0.5751 52 Week Range 1.79
Market Cap
56.524M
Previous Close
0.88
Open
0.8638
Last Trade
23
@
0.9155
Last Trade Time
Financial Volume
$ 71,388
VWAP
0.888306
Average Volume (3m)
132,061
Shares Outstanding
61,640,596
Dividend Yield
-
PE Ratio
-0.56
Earnings Per Share (EPS)
-1.66
Revenue
-
Net Profit
-102.06M

About Passage Bio Inc

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.passagebio.com/home/default.aspx
Headquarters
Wilmington, Delaware, USA
Founded
1970
Passage Bio Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker PASG. The last closing price for Passage Bio was $0.88. Over the last year, Passage Bio shares have traded in a share price range of $ 0.5751 to $ 1.79.

Passage Bio currently has 61,640,596 shares outstanding. The market capitalization of Passage Bio is $54.24 million. Passage Bio has a price to earnings ratio (PE ratio) of -0.56.

PASG Latest News

More News

Form 8-K - Current report

July 16 2024
Edgar (US Regulatory)

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations...

July 16 2024
GlobeNewswire Inc.

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

June 05 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

May 23 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 22 2024
Edgar (US Regulatory)

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...

May 21 2024
GlobeNewswire Inc.

Form 424B3 - Prospectus [Rule 424(b)(3)]

May 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 14 2024
Edgar (US Regulatory)

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months post-treatment in the two patients with...

May 14 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0273.033707865170.890.920.77161148550.85432798CS
4-0.033-3.473684210530.951.030.77161870760.9083145CS
12-0.423-31.56716417911.341.640.77161320611.06974311CS
260.0171.888888888890.91.790.77162407311.29729223CS
520.0475.402298850570.871.790.57513216000.98363552CS
156-11.803-92.790880503112.7213.430.57513103632.85939624CS
260-21.353-95.882352941222.2738.230.57513059707.92609338CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WINTWindtree Therapeutics Inc
$ 8.24
(150.46%)
48.57M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NBSTWNewbury Street Acquisition Corporation
$ 0.1349
(92.71%)
122.1k
YIBOPlanet Image International Ltd
$ 2.915
(53.43%)
260.07k
CREVCarbon Revolution Public Ltd
$ 9.00
(45.87%)
8.06M
NMHINatures Miracle Holding Inc
$ 0.2035
(-48.06%)
7.69M
TANHTantech Holdings Ltd
$ 0.2585
(-47.23%)
6.75M
DXCMDexCom Inc
$ 64.00
(-40.66%)
53.92M
PSIGPS International Group Ltd
$ 1.42
(-31.40%)
716.26k
POAIPredictive Oncology Inc
$ 1.36
(-27.27%)
6.02M
SLNASelina Hospitality PLC
$ 0.0305
(-18.88%)
408.61M
BFIBurgerFi International Inc
$ 0.4206
(97.37%)
313.59M
NVDANVIDIA Corporation
$ 113.06
(0.69%)
293.33M
SQQQProShares UltraPro Short QQQ
$ 9.10
(-2.88%)
176.49M
SGMOSangamo Therapeutics Inc
$ 0.8612
(28.15%)
123.71M

PASG Discussion

View Posts
Monksdream Monksdream 3 weeks ago
There are close to 1,000 listed med tech companies
Only so many can garner serious institutional interest
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
I wonder... when will people realize that the AAV stuff is great... CADL, SLDB, PASG

The founder certainly thinks so... and he is the authority on the topic:
"Dr. James M. Wilson serves as the Director of the Gene Therapy Program (GTP) at Penn's Perelman School of Medicine."

"The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy.The Wilson lab identified a new type of vector based on novel isolates of adeno-associated viruses which have become best in class for gene therapy. More recently Dr. Wilson’s laboratory has focused on improved vectors for gene therapy and clinical applications of genome editing and mRNA therapy."
👍️0
Monksdream Monksdream 2 months ago
PASG under $2
👍️0
Monksdream Monksdream 3 months ago
PASG under $2
👍️0
Sirpeter Sirpeter 4 months ago
Running... boom!!!
👍️0
Monksdream Monksdream 4 months ago
PASG under $2
👍️0
glenn1919 glenn1919 4 months ago
PASG..........................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
PASG new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
PASG setting up nicely. Another beautiful call by the only true chartist around
👍️0
Sirpeter Sirpeter 5 months ago
Yup yup yup...
👍️0
TrendTrade2016 TrendTrade2016 5 months ago
PASG...NEXT CRDL
👍️0
glenn1919 glenn1919 5 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
PASG..............................https://stockcharts.com/h-sc/ui?s=PASG&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
PASG under $2
👍️0
turning stone turning stone 6 months ago
As a new investor in PASG, I am looking forward to another high roller in the next number of years. I bought ARNA years ago at 1.90 and rode it out to $99/share when they were bought out by Phizer Pharm. I would like to have my 5 grandkids share the spoils on this one. With a multi-pipe line, a couple should make it to the end of the line with FDA approval. At the number of shares I purchased multiple times I can afford to run for the hills if a sudden disaster should hit this one. This company is 21 miles from my home and I will stop by shortly and have a sit down with their home-based PR. person. Good luck to all. You may also want to look at BLRX {BIO-Line Inc }










👍️0
Walter4 Walter4 7 months ago
Data readout should be incoming shortly
👍️ 1
Monksdream Monksdream 11 months ago
PASG new 52 week low
👍️0
catinhat catinhat 2 years ago
So...anybody out there? Thoughts on upcoming abstract, etc?

Recent long.
👍️0
dealerschool2006 dealerschool2006 4 years ago
PASG down from panic selling due to the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $22.00 per share.
👍️0

Your Recent History

NASDAQ
PASG
Passage Bio
BINA
FLOKIUSDT
FLOKI
LSE
PREM
Premier African Minerals
LSE
PHAR
Pharos Energy
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved